Clobazam and Metabolite, Quantitative, Serum or Plasma
Also known as: CLOBAZAM
Use
Clobazam is a benzodiazepine drug indicated for adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients 2 years and older. This test is used to optimize drug therapy and monitor patient adherence by measuring the concentration of clobazam and its metabolite, N-desmethylclobazam, in serum or plasma. Therapeutic drug monitoring helps in adjusting doses for efficacy and minimizing adverse effects such as constipation, somnolence, sedation, and skin rash. Monitoring is particularly important in patients with poor CYP2C19 metabolism and those using other CNS depressants due to potential drug interactions.
Special Instructions
Not provided.
Limitations
The pharmacokinetics of clobazam are influenced by drug-drug interactions and by poor CYP2C19 metabolism. Adverse effects may increase when clobazam is used concomitantly with other CNS depressants. Interpretive considerations include differentiating therapeutic from toxic levels and understanding that the metabolite, N-desmethylclobazam, retains about 20% of the activity of the parent drug.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 3487-6 - cloBAZam SerPl-mCnc
- 35107-2 - Norclobazam SerPl-mCnc
Result Turnaround Time
1-6 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2 mL
Minimum Volume
0.3 mL
Container
ARUP standard transport tube
Collection Instructions
Separate from cells ASAP or within two hours of collection. Transfer serum or plasma to an ARUP standard transport tube.
Storage Instructions
Refrigerated is preferred. Also acceptable: Room temperature or frozen.
Causes for Rejection
Gel separator tubes, hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 3 days |
| Refrigerated | 2 weeks |
| Frozen | 2 months |
Other tests from different labs that may be relevant